Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, education and media company The Washington Post
With that in mind, let's take a closer look at Washington Post's business and see what CAPS investors are saying about the stock right now.
Washington Post facts
|Headquarters (founded)||Washington, D.C. (1877)|
|Market Cap||$3.0 billion|
|Trailing-12-Month Revenue||$4.2 billion|
|Management||Chairman/CEO Donald Graham
Executive Editor Marcus Brauchli
|Return on Equity (average, past 3 years)||7%|
|Cash/Debt||$719.8 million / $567.3 million|
The New York Times
Sources: S&P Capital IQ; Motley Fool CAPS.
On CAPS, 22% of the 259 members who have rated Washington Post believe the stock will underperform the S&P 500 going forward.
Earlier this week, one of those Fools, bossman5000, succinctly summed up the bear case for our community: "If I had to pick one company to short, it might be the [Washington Post Company]. The newspaper division isn't going anywhere and counting on Kaplan, which has been dogged by controversy surrounding expensive classes and poor curriculum, is not sustainable."
If you want to retire rich, you need to protect your portfolio from any undue risk. Luckily, we've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.
More from The Motley Fool
What's Juno Therapeutics Worth to Celgene?
Celgene may be considering a multibillion-dollar bid to acquire Juno.
Why Ascena Retail Group Inc. Stock Plunged 62% in 2017
The parent company of maurices just finished a tough year. Here's what investors need to know.
3 Easy Ways to Invest in India for 2018
Here's how to get access to this exciting emerging market.